Explore the Potential with AI-Driven Innovation
This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.
From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Our collaborator, Reaxense, aids in their synthesis and provision.
The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.
We use our state-of-the-art dedicated workflow for designing focused libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
The procedure entails thorough molecular simulations of the catalytic and allosteric binding pockets, accompanied by ensemble virtual screening that factors in their conformational flexibility. When developing modulators, the structural modifications brought about by reaction intermediates are factored in to optimize activity and selectivity.
Key features that set our library apart include:
partner
Reaxense
upacc
U3KPV4
UPID:
A3LT2_HUMAN
Alternative names:
Isoglobotriaosylceramide synthase
Alternative UPACC:
U3KPV4
Background:
Alpha-1,3-galactosyltransferase 2, also known as Isoglobotriaosylceramide synthase, plays a crucial role in synthesizing the galactose-alpha(1,3)-galactose group on glycosphingolipid isoglobotrihexosylceramide. It catalyzes the transfer of galactose from UDP-Galactose to Gal-beta-1,4-Glc-ceramide and can further modify iGb3 to form polygalactose structures.
Therapeutic significance:
Understanding the role of Alpha-1,3-galactosyltransferase 2 could open doors to potential therapeutic strategies.